



**YORK AGAINST CANCER**

**A company limited by guarantee  
and  
A registered charity number 1130835**

**REPORT AND ACCOUNTS**

**For the year ended**

**31 December 2021**

**HPH  
Chartered Accountants  
54 Bootham  
York  
YO30 7XZ**

## **YORK AGAINST CANCER**

### **CONTENTS**

	<b>Page</b>
<b>Chairman's Report</b>	<b>1</b>
<b>Trustees' Report</b>	<b>2 - 13</b>
<b>Auditor's Report</b>	<b>14 – 17</b>
<b>Statement of Financial Activities</b>	<b>18</b>
<b>Balance Sheet</b>	<b>19</b>
<b>Cash Flow Statement</b>	<b>20</b>
<b>Notes to the Financial Statements</b>	<b>21 - 31</b>

## **YORK AGAINST CANCER**

### **CHAIRMAN'S REPORT 2021**

2021 remained a challenging year with lockdowns continuing and numerous restrictions on personal liberty running throughout much of the year. As a result, much of our work was again affected, but as the months passed, we were at last getting back to something like normal.

It was a great tonic to see many of our volunteers as the year progressed, and as most of you will be much aware we have, at last, moved into our new premises at the Community Stadium.

Our small team continued to work hard throughout the year, and to them, our volunteers, and Board colleagues I would like to pass on my grateful thanks for continuing to promote the Charity during a really difficult period.

Work of course continued, and the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be ever more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

We sadly lost a number of our volunteers throughout the year, and our thoughts go out to their families, and we wish them well for the future. Every one of them supported the day to day work of the Charity, and helped the Charity to continue to provide the important services and funding for research that the we are recognised for.

Despite the ongoing restrictions, our minibus service continued to operate in difficult conditions, and special thanks go to drivers Ian and Neil for providing this vitally important service when many other cancer services were still curtailed by the NHS. Ian retired in May and subsequently welcomed Garry. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

A number of projects are under evaluation for the coming year, and I very much hope the Chair's report for 2022 will be much more representative of the positive things the Charity is able to deliver.

**Ian Yeowart**

**Chair York Against Cancer**

## **YORK AGAINST CANCER**

### **DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2021.

#### **Objectives and activities**

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

#### **Aims and strategies**

The Charity aims to provide support to cancer patients and the community through the: -

- funding and the provision of services and resources for patients and their families
- funding of research programmes
- funding of education initiatives

#### **Achievements and performance**

### **SUPPORT ACTIVITIES**

#### **Support Team**

The small team of hardworking office staff deal effectively with all aspects of the day-to-day operation of the charity, and it is worth noting that during 2021 there has been an inevitable impact on fundraising and charity/staff/board morale and the charity have striven to deal with those demands and risen to meet the challenges head on.

The relocation of the office and one of the retail outlets into the York Community Stadium was managed by the staff and was completed on the May 14th. As well as an increased amount of much needed space, the new environment facilitates opportunities to form new relationships with stakeholders.

The team's work is sometimes challenging as they deal with people facing cancer and on occasions, this can impact on their resolve, however, they deal with this together and their teamwork is impressive. The team are friendly and often are found smiling. The way it is possible for our manager and her staff to respond quickly to any requests or challenges is a key strength for York Against Cancer as a local charity.

## YORK AGAINST CANCER

### DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

#### SUPPORT ACTIVITIES

##### Mobile Chemotherapy Unit



The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients the time-consuming and tiring journeys to the hospital in York. During the Covid pandemic the MCU was repurposed and used as a standalone cancer department at the Scarborough hospital site.

##### Respite Properties

The Respite house in Filey continues to provide a welcome break; cancer patients and their families are offered either a three-day weekend or four-day weekday break. The many letters of appreciation we receive are an indication of how much a short break in the luxurious surroundings is appreciated.

During 2021 the YAC board decided to sell the Whitby apartment; the property had been popular however there were increasing problems with the upkeep of the property. The board, are looking into extending this service, in the near future, and are through exploring opportunities to buy an additional property.

##### Minibus

Our minibus service has also been affected by Covid, for a few months it was not able to run but as soon as the restrictions allowed it resume, however, with a restricted number of passengers. It continues to be an excellent and much-valued service of transporting patients to St. James' Hospital.

The thoughtful and kind approach of our minibus drivers has also again been very much appreciated.



## **YORK AGAINST CANCER**

### **DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

#### **SUPPORT ACTIVITIES**

##### **Posts and services supported by York Against Cancer**

In addition to the team directly employed by the charity there are other support workers whose salary costs are paid by York Against Cancer. These posts are itemised below and illustrate the range of activities supported by the Board:

- **Health Care Assistant**

The Health Care Assistant continued to provide support for families affected by cancer until November 2021. These appointments are made in conjunction with the NHS to provide support for patients and their families; support which is not available through the normal NHS services.

- **Complementary Therapy**

Complementary therapy arranged through the Cancer Care Centre has been significantly affected by Covid-19 and patients have been offered complementary therapy and other services virtually until April 2021.

- **Clinical Research Nurse and Assistant posts at York Hospital**

During the pandemic, some research nurses were still able to keep some Oncology Research going and three new studies were opened near the year end.

- **Health Welfare Advisor**

The charity continues to support the Citizens Advice Bureau in their work with cancer patients at Scarborough hospital: this work provides support for those having cancer treatment and based at Scarborough to ensure that they receive all the help to which they are entitled.

All these supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

The services have been hindered by the closure of the Cancer Care Centre at the hospital during the year. The charity committed to opening a new centre fully funded by the charity. The Leveson Centre is due to open in 2022 at the York Community Stadium. The Centre will offer a wide range of holistic cancer support services to complement the clinical treatments provided at York Hospital.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

**RESEARCH ACTIVITIES**

**Jack Birch Unit (University of York)**

The Charity is committed to another 3 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

**Jack Birch Unit of Molecular Carcinogenesis**

For the JBU, 2021 was a challenging year with limits on occupancy in the labs and constant changing of rules applied variously to staff and students. We faced some difficulties with obtaining laboratory supplies and our usual collection of surgical samples from our NHS colleagues took a big hit. Nevertheless, the JBU esprit de corps kicked in and the group worked together as a team, with weekly laboratory meetings and bimonthly lab management meetings held via zoom. Placement Masters and Undergraduate students, hoping for lab experience were most affected, as their projects became virtual. One third year BSc student, Sophie Curran worked with the YAC office on a successful science communications project looking at the use of Instagram to spread information to younger people about the risks and early signs of cancer.

We had a few staff changes. Richard Gawne joined Dr Andrew Mason's group as a bioinformatician and Katie Skinner left to take up her PhD position in Atlanta. Ben Jarvis completed a Masters by Research and left to take up a PhD position in Manchester. Dr Sreemoti Banerjee moved to a postdoc job in Leeds and Dr Annu Joseph joined us as a postdoc on a new Wellcome LEAP grant on kidney engineering – part of a collaboration with colleagues at University College London and the Universities of Edinburgh and Manchester.

In October 2021, Simon Baker caught COVID in the delta wave, testing positive 48 hours before the most important interview of his career. So we are delighted to report that following his interview, Simon was awarded a prestigious Kidney Research UK fellowship to continue his work in the JBU. YAC funding has been critical to Simon's work, which is investigating a childhood virus as the possible cause of bladder cancer and he could not have achieved any of this without YAC's support.



## **YORK AGAINST CANCER**

### **DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

#### **RESEARCH ACTIVITIES**

One of the advantages with zoom is that we were able to participate in virtual workshops and meetings with international audiences. For a flavour of these, Dr Andrew Mason organised a very successful workshop on Disruptive 'Omics Technologies in Molecular Medicine in March, and I chaired, and Dr Simon Baker presented at, sessions of the 3<sup>rd</sup> Bladder Cancer Translational Research Meeting in May. Between us, the JBU published eight scientific papers and one book chapter during 2021.

As the labs became more accessible in late 2021, Lauren and Hayley visited the JBU to take away some news stories to share with YAC. I am always delighted to show off our brilliant laboratories to visitors, so please do feel free to contact the YAC office or me directly, if you would like to arrange a visit.

I would like to thank York Against Cancer Board, fundraisers and supporters for the research support we receive. I also gratefully acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.

**Professor Jenny Southgate, Director,  
Jack Birch Unit of Molecular Carcinogenesis, University of York**

#### **EDUCATION ACTIVITIES**

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

##### **York Against Cancer Education and Awareness Committee Report 2021.**

Firstly, can I pass on my thanks to Stuart Parker (outgoing Chair) and the other members of the team who have continued to work hard despite the constraints of the Covid -19 pandemic. Our small but committed team has continued to meet via zoom this year.

The Enthuse partnership remained stalled due to the pandemic, but the funding will be rolled forward to a point in time when teachers are able to participate in the project. I hope we will have a positive update on this project in 2022.

After not being able to distribute sun hats and sun awareness leaflets into schools in 2020, we are pleased to announce that in 2021 this annual delivery restarted. Our committed volunteers help us with the distribution to the participating schools.

We held a cancer awareness day at Vanguard for the first time, this proved to be successful. The day helped launch the sale of our Christmas cards and drew attention to the relocation of the shop to the Community Stadium site. The committee recommended to the Board that we consider having two awareness day's a year – one in the city centre and one at Vanguard/Community Stadium.

We have distributed 317 picture books to schools to support children who are affected by cancer. Thank you to the office and volunteers who supported this project and delivered books into local schools.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

**EDUCATION ACTIVITIES**

Stuart mentioned in his 2020 report that the committee had undertaken a brainstorming session, during 2021 we narrowed our ideas down! With Covid restricting our work with schools, the committee decided to look at how we could raise awareness in the community of signs and symptoms of cancers and the screening that is available. We wanted to focus our attention on underrepresented groups or cancers with poor screening uptakes. Unfortunately, it has taken longer to access this information than we anticipated so we have not made as much progress as we would all have liked.

In collaboration with the Communication committee, we have had preliminary discussions on how to achieve a physical as well as a digital presence across the whole YAC region.

Thank you to Julie and her team, as well as to committee members Stuart, Simon, Joan and Jane. We hope that 2022 will see an increase in our committee membership, that Enthuse takes off and we are able to put into action our plans for raising awareness as well as continuing our work with primary schools.

**Lynn Bartram**

**Chair, Education and Awareness group**

**FUTURE PLANNING**

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

Future projects include: -

- **Robotic Surgery** – Supporting the running costs of new robotic surgery equipment used in cancer treatments at York Hospital over 3 years.
- **The Leveson Centre** – Fit out and running costs of a new centre to offer a wide range of holistic cancer support services.
- **Current projects** – Ongoing support for current committed projects.

## **YORK AGAINST CANCER**

### **DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

#### **FUNDRAISING**

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful 'shop front' for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2021 in relation to its fundraising activities.

#### **Fundraising report 2021**

Following on from 2020, 2021 proved to be another tricky year for fundraising. We had some events planned that had to be postponed or just simply did not happen - for example York Rocks Against Cancer. However, we did still have some larger fundraisers, such as the golf day and the Dragon Boat race, that did go ahead and were very successful. This year, we have been supported by Marks and Spencers Vangarde, Forest of Galtres golf club, Sainsburys Monks Cross, JWP Creers and Iceland at Clifton Moor.

Our supporters have done a fantastic job moving with the times and finding ways to fundraise even though we could not be together, something just as simple as a group of friends putting £1 away each week raised £370. We also benefitted from the Jack Birch Unit who launched a successful run/walk 50k in 10 days fundraiser for us while we were still locked down. The combination of our own events and support from the local people of York and the surrounding areas has meant that, although some momentum has been lost, York Against Cancer has been kept going through a really difficult time. We are so grateful to the people who take the time to raise money for us, we simply would not be here without their help.

Overall, we have managed to carry on where we can and adapt where necessary to make the most of the events, we have been able to hold. We have also been able to broaden our income stream by improving our online donating facilities as well as encouraging online donations and investing in tap to donate. We are so grateful to all our supporters who have continued their support through another tricky year. We are very much looking forward to a brighter year ahead.

**Lauren Hudson**

**Head of Fundraising and Executive Assistant**

## DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

### Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

### Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

### Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to one Board member, Tarnia Hudson, who serves as the Honorary Administrator.

The members of staff employed by the Charity during the year were:

Julie Russell	General Manager
Heather Atkinson	Office & Accounts Manager
Lauren Hudson	Personal Assistant to General Manager
Nicola Doherty	Office & Volunteer coordinator
Helen Watkinson	Retail Manager until 26 <sup>th</sup> November 2021
Francine Clee	PR & Communications Officer P/T until 14 <sup>th</sup> May 2021
Hayley Johnson	Communications Manager P/T from 5 <sup>th</sup> July 2021
Ian Stephenson	Minibus Driver P/T until 25 <sup>th</sup> May 2021
Neil Johnson	Minibus Driver P/T
Garry Stanton	Minibus Driver P/T from 27 <sup>th</sup> May 2021

### Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term up to a maximum of 9 years in total (details of current terms of office available on request).

### Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

**Related parties**

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

**Risk management**

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects. The relocation to the York Community Stadium in May 2021 provides greater storage and office space and a retail outlet with a good footfall.

It should be emphasised that supporting staff not directly employed by York Against Cancer is always done on a time-limited basis (typically two years) which is renewed as appropriate provided funds are available. The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

**Financial review and policies**

The Charity's funds in 2021 increased by £495,416. Large investment gains have further increased the surplus made. Prior to any adjustment for investments, the Charity made a surplus of £109,854 (2020 deficit of £146,787). The charity only generated a surplus in the year as the Mobile Chemotherapy Unit came in under budget in prior years and the excess commitment of £109,763 was released in the year. The future running costs of the unit will be cover by the remaining restricted fund.

The principal funding sources are fund-raising, the trading shops, donations, and legacies. Gross income in 2021 amounted to £647,704 (2020 £389,859). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

£143,861 (2020 £163,187) was committed on project expenditure, to support the Charity's ongoing projects. The already committed projects cash spend was a further £447,546.

Due to COVID-19 there were limited additional projects taken on this year however two large projects not let confirmed at the year-end have been since committed two since the year end. These are the Robotic Surgery and The Leveson Centre.

The detail of funding of projects can be found in note 6.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

**Investment powers and policy**

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2021. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2021, before fees, was 10.99% (2020 0.43%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2021, before fees, was 11.80% (2020 11.88%).

**Reserves Policy**

The reserves policy is to generate a stable and sustainable return to fund grant making, to ensure continued financial security and to provide for contingencies. Cash reserves are accumulated before making a binding commitment to fund a project due to the nature and uncertainty of the income streams. The total funds held as at 31 December 2021 are £4,778,060 (2020 £4,282,644).

The Board is very mindful that the charity has a substantial reserve of funds at present after the receipt of some large legacies. The board is actively seeking to find effective ways in which these can be utilized to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

**Undesignated Fund**

These are free reserves retained to provide working capital and funds for future projects. At the end of the financial year, the free reserves were £3,041,746 (2020 £3,503,531) accumulated largely due to the receipt of several generous legacies, which by their very nature are unpredictable. The level of free reserves will enable the Charity to give significant support to worthwhile projects which make a measurable impact.

**Designated Funds**

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £1,597,671 (2020 £635,088) details of which are given in Note 16 of the financial statements.

**Restricted Funds**

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £138,643 (2020 £144,025) details of which are given in Note 17 to the financial statements.

COVID-19 has had a significant impact on donations and fundraising since April 2020. The charity has significant reserves brought forward and these will be used to help support the charity adapt where needed and keep its on-going commitments.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

**Directors and Trustees Responsibilities**

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

Approved by the Board on 22 September 2022 and signed on its behalf by:

Ian Yeowart  
*Director and Trustee*

# YORK AGAINST CANCER

## DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

### Reference and administrative details

Registered Charity	number 1130835	Company Limited by Guarantee	number 06884476
Principal Office and Trading Address	East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF		
Company Secretary	Julie Pamela Russell		
Directors and Trustees	Andrew Proctor Angela Darby Rachel Goddard Michael John Stower William Mark Sessions Ian Yeowart Sarah Wearing	Dr Lynn Bartram Michael Sweet Robert Onyett Tarnia Hudson Prof Stephen Leveson Michael Patrick Shepherd	
	Trustee's protocol available on request		
Accountants	HPH Chartered Accountants 54 Bootham York YO30 7XZ	Auditors	Hentons & Co LLP Chartered Accountants 124 Acomb Road Holgate York YO24 4EY
Bankers	National Westminster Bank 1 Market Street York YO1 8SR	Solicitors	Harrowells Moorgate House Clifton Moorgate York YO30 4WY
Investment Advisors	HSBC Global Asset Management 78 St James's Street London SW1A 1EJ		Ruffer LLP 80 Victoria Street London SW1E 5JL

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER  
YEAR ENDED 31 DECEMBER 2021**

**Opinion**

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2021 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2021 and of the groups incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER  
YEAR ENDED 31 DECEMBER 2021**

We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report have been prepared in accordance with applicable legal requirements.

**Matter on which we are required to report by exception**

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

**Responsibilities of the trustees**

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER  
YEAR ENDED 31 DECEMBER 2021**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

- We have obtained an understanding of the legal and regulatory framework applicable to the group and parent charitable company through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the charitable company is a part of. The charitable company uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the company remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the group and charitable company; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the group's and charitable company's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2021.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the group's and charitable company's controls, and the nature, timing and extend of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

## **YORK AGAINST CANCER**

### **INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER**

**YEAR ENDED 31 DECEMBER 2021**

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's and charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### **Use of our report**

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....  
**Brett Davis (Senior Statutory Auditor)**

**For and on behalf of Hentons**

**Chartered Accountants**

**Statutory Auditor**

124 Acomb Road

York

YO24 4EY

**Date: 22 September 2022**

**YORK AGAINST CANCER**  
**CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES**  
**AND INCOME AND EXPENDITURE ACCOUNT**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

	Note	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2021 £	Year ended 31 Dec 2020 £
<b>Income and endowments from:</b>						
Donations and legacies	2	403,515	-	-	403,515	182,705
Other trading activities	3	199,087	-	-	199,087	157,863
Investments	4	45,102	-	-	45,102	49,291
<b>Total</b>		<b>647,704</b>	<b>-</b>	<b>-</b>	<b>647,704</b>	<b>389,859</b>
<b>Expenditure on:</b>						
Raising funds	5	199,970	-	-	199,970	181,336
Charitable activities	6	325,394	7,104	5,382	337,880	355,310
<b>Total</b>		<b>525,364</b>	<b>7,104</b>	<b>5,382</b>	<b>537,850</b>	<b>536,646</b>
<b>Net income/(expenditure) before gains on investments</b>		<b>122,340</b>	<b>(7,104)</b>	<b>(5,382)</b>	<b>109,854</b>	<b>(146,787)</b>
Net gains on investments	11	385,562	-	-	385,562	171,077
<b>Net income/(expenditure)</b>		<b>507,902</b>	<b>(7,104)</b>	<b>(5,382)</b>	<b>495,416</b>	<b>24,290</b>
<b>Transfers between funds</b>	16	<b>(969,687)</b>	<b>969,687</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net movement in funds</b>		<b>(461,785)</b>	<b>962,583</b>	<b>(5,382)</b>	<b>495,416</b>	<b>24,290</b>
<b>Reconciliation of funds:</b>						
Total funds brought forward		3,503,531	635,088	144,025	4,282,644	4,258,354
<b>Total funds carried forward</b>		<b>£ 3,041,746</b>	<b>£ 1,597,671</b>	<b>£ 138,643</b>	<b>£ 4,778,060</b>	<b>£ 4,282,644</b>

*The notes on pages 21 to 31 form part of these financial statements.*

**YORK AGAINST CANCER**  
(Registration number: 06884476)

**BALANCE SHEET**  
**AS AT 31 DECEMBER 2021**

	Note	Charity 2021 £	Consolidated 2021 £	Charity 2020 £	Consolidated 2020 £
<b>FIXED ASSETS</b>					
Tangible Fixed Assets	12	362,264	405,171	573,526	585,342
Investments	11	4,076,185	4,076,184	3,741,011	3,741,010
		<u>4,438,449</u>	<u>4,481,355</u>	<u>4,314,537</u>	<u>4,326,352</u>
<b>CURRENT ASSETS</b>					
Stock		-	55,176	-	55,295
Debtors	13	540,858	449,771	551,936	462,285
Cash at Bank and in Hand		819,603	846,463	827,681	898,835
		<u>1,360,461</u>	<u>1,351,410</u>	<u>1,379,617</u>	<u>1,416,415</u>
<b>CREDITORS: amounts falling due within one year</b>	14	498,519	517,503	487,559	499,107
		<u>861,942</u>	<u>833,907</u>	<u>892,058</u>	<u>917,308</u>
<b>NET CURRENT ASSETS</b>					
		861,942	833,907	892,058	917,308
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>					
		5,300,391	5,315,262	5,206,595	5,243,660
<b>CREDITORS: amounts falling due after one year</b>	15	537,202	537,202	961,016	961,016
		<u>£ 4,763,189</u>	<u>£ 4,778,060</u>	<u>£ 4,245,579</u>	<u>£ 4,282,644</u>
<b>NET ASSETS</b>					
		<u>£ 4,763,189</u>	<u>£ 4,778,060</u>	<u>£ 4,245,579</u>	<u>£ 4,282,644</u>
<b>THE FUNDS OF THE CHARITY</b>					
<b>Unrestricted</b>					
Undesignated	18	3,069,782	3,041,746	3,478,282	3,503,531
Designated	16,18	1,554,764	1,597,671	623,272	635,088
<b>Restricted</b>	17,18	138,643	138,643	144,025	144,025
<b>TOTAL CHARITY FUNDS</b>		<u>£ 4,763,189</u>	<u>£ 4,778,060</u>	<u>£ 4,245,579</u>	<u>£ 4,282,644</u>

Approved by the Trustees on 21 September 2022 and signed on its behalf by:

S B Wearing  
Director and Trustee

The notes on pages 21 to 31 form part of these financial statements.

**YORK AGAINST CANCER  
CONSOLIDATED CASHFLOW STATEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Note	2021 £	2020 £
<b>Cash flows from operating activities:</b>			
<b>Net cash used in operating activities</b>	<b>21</b>	(335,263)	(363,320)
<b>Cash flows from investing activities:</b>			
Dividends, interest and rents from investments		45,102	49,291
Purchase of property, plant and equipment		(64,330)	(2,990)
Proceeds from sale of property		251,731	-
Proceeds from sales of investments		1,838,749	1,095,488
Purchase of investments		(1,788,361)	(1,117,345)
<b>Net cash provided by investing activities</b>		<u>282,891</u>	<u>24,444</u>
<b>Change in cash and cash equivalents in the reporting period</b>		(52,372)	(338,876)
<b>Cash and cash equivalents at the beginning of the reporting period</b>		<u>898,835</u>	<u>1,237,711</u>
<b>Cash and cash equivalents at the end of the reporting period</b>		<u><u>£ 846,463</u></u>	<u><u>£ 898,835</u></u>

*The notes on pages 21 to 31 form part of these financial statements.*

## YORK AGAINST CANCER

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

#### 1. ACCOUNTING POLICIES

##### **Legal entity**

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

##### **Basis of preparation**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

##### **Going Concern**

The Charitable Company has cash resources and has no requirement for external funding. The cash and investments held are sufficient to see the Charitable Company through the financial impact of COVID-19. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

##### **Income**

###### Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

###### Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

###### Investments

Investment income has been accounted for on an accruals basis.

##### **Expenditure**

###### Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

###### Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

## YORK AGAINST CANCER

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

#### 1. ACCOUNTING POLICIES (continued)

##### Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

##### Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property	at straight line over 50 years
Equipment	
- Shop and office equipment	at straight line over 10 years
- Computer equipment	at straight line over 3 years
- Respite home equipment	at straight line over 4 years
- Motor vehicles	at 25% reducing balance

##### Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

##### Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

##### Investments

The investment portfolios have been valued at market value at 31 December 2021. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

##### Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

##### Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

##### Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

##### Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

##### Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

##### Government grants

These government grants relate to the COVID grants for retail closures issued to the subsidiary trading company.

**YORK AGAINST CANCER**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2021**

<b>2. DONATIONS AND LEGACIES</b>	<b>Unrestricted £</b>	<b>Restricted £</b>	<b>2021 £</b>	<b>2020 £</b>
Donations	158,533	-	158,533	118,189
In Memoriam	19,852	-	19,852	24,957
Legacies	206,699	-	206,699	13,225
Government grant	13,431	-	13,431	21,334
Intangible income	5,000	-	5,000	5,000
	<u>£ 403,515</u>	<u>£ -</u>	<u>£ 403,515</u>	<u>£ 182,705</u>

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

<b>3. OTHER TRADING ACTIVITIES</b>	<b>2021 £</b>	<b>2020 £</b>
Fundraising income	99,601	72,639
Subsidiary's non-charitable trading turnover	99,486	85,224
	<u>£ 199,087</u>	<u>£ 157,863</u>

<b>4. INVESTMENTS</b>	<b>2021 £</b>	<b>2020 £</b>
Interest received	627	2,696
Dividends received	44,475	46,595
	<u>£ 45,102</u>	<u>£ 49,291</u>

<b>5. ANALYSIS OF RAISING FUNDS</b>	<b>Unrestricted £</b>	<b>Restricted £</b>	<b>2021 £</b>	<b>2020 £</b>
Advertising	11,292	-	11,292	7,900
Fundraising costs	36,933	-	36,933	65,847
Non charitable trading - other costs	110,546	-	110,546	70,995
Non charitable trading - staff costs	21,123	-	21,123	22,165
Non charitable trading - depreciation	5,156	-	5,156	2,515
Investment fees	14,920	-	14,920	11,914
	<u>£ 199,970</u>	<u>£ -</u>	<u>£ 199,970</u>	<u>£ 181,336</u>

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2021

6. ANALYSIS OF CHARITABLE ACTIVITIES

<i>Direct project costs:</i>	Unrestricted £	Restricted £	2021 £	2020 £
<b>Research</b>				
Clinical Trial Nurses	95,051	-	95,051	19,239
<b>Support and Care</b>				
Cancer Care Centre - Old	6,511	-	6,511	26,330
Complementary therapy	-	-	-	29,541
Health Care Assistant	12,818	-	12,818	7,865
Respite property expenses	21,103	-	21,103	29,257
Minibus running costs - direct	12,248	-	12,248	7,029
Minibus running costs - staff costs	20,439	-	20,439	18,533
Mobile Chemotherapy Unit*	(109,763)	5,382	(104,381)	321
Psychology services	4,040	-	4,040	5,680
Restricted grants	-	-	-	12,222
Health Welfare Advisor	73,444	-	73,444	-
<b>Education</b>				
Education expenses	2,588	-	2,588	7,170
	138,479	5,382	143,861	163,187
*During the year the underspend on the Mobile Chemotherapy Unit was released as the project cost less than initially budgeted. Running costs are covered by the restricted funds.				
<b>Support costs:</b>				
Staff costs	139,079	-	139,079	134,916
Staff training and travel	2,553	-	2,553	1,702
Rent, service charge and rates	21,779	-	21,779	4,352
Heat and light	1,837	-	1,837	1,666
Repairs and maintenance	173	-	173	1,932
Insurances	3,416	-	3,416	2,963
Printing, stationery and postage	4,870	-	4,870	4,856
Computer expenses	7,819	-	7,819	7,867
Telephone	2,693	-	2,693	1,710
Sundry expenses	6,384	-	6,384	3,953
Gains and losses on fixed assets	(28,554)	-	(28,554)	-
Depreciation	16,168	-	16,168	13,500
	178,217	-	178,217	179,417
<b>Governance costs:</b>				
Audit fees	4,560	-	4,560	3,480
Accountancy fees	7,507	-	7,507	7,663
Legal fees	2,182	-	2,182	-
Bank charges	1,553	-	1,553	1,563
	15,802	-	15,802	12,706
Total charitable activities	£ 332,498	£ 5,382	£ 337,880	£ 355,310

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

### 7. NET INCOMING RESOURCES FOR THE YEAR

	2021 £	2020 £
This is stated after charging:		
Depreciation	21,324	18,530
Auditor's remuneration for audit services - charity	4,560	3,480

### 8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

### 9. STAFF COSTS

	2021 £	2020 £
Wages and salaries	160,955	155,368
Social security costs	8,614	8,710
Pension costs	6,701	7,104
Medical Insurance	4,371	4,432
	<u>£ 180,641</u>	<u>£ 175,614</u>

The average monthly head count was 8 staff (2020 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Projects	1	1
Trading	1	1
Management and administration	6	6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees and the General Manager. The total employee benefits of the key management personnel of the Charitable Company were £50,303 (2020 - £49,937).

### 10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £92,808 (2020 £95,637). Interest of £186 (2020 £141) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

	2021 £	2020 £
Turnover	99,486	85,224
Cost of sales	<u>(64,071)</u>	<u>(46,891)</u>
Gross profit	35,415	38,333
Administrative expenses	<u>(72,754)</u>	<u>(48,953)</u>
Operating profit	(37,339)	(10,620)
Other operating income	15,333	11,334
Interest payable	<u>(186)</u>	<u>(141)</u>
Profit on ordinary activities before taxation	(22,192)	573
Taxation	-	-
Profit on ordinary activities after taxation	(22,192)	573
Amount gifted to York Against Cancer	-	-
Retained (withdrawn from)/within Subsidiary	<u>£ (22,192)</u>	<u>£ 573</u>
Net Assets	<u>£ 14,871</u>	<u>£ 37,063</u>

**YORK AGAINST CANCER**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2021**

**11. INVESTMENTS**

<b>Consolidated</b>	<b>2021 £</b>	<b>2020 £</b>
Market value at 1 January 2021	3,741,010	3,548,076
Additions at cost	1,788,361	1,117,345
Disposals	(1,838,749)	(1,095,488)
Revaluations	385,562	171,077
Market value at 31 December 2021	<u>£ 4,076,184</u>	<u>£ 3,741,010</u>
Analysis of investments by class:		
Listed investments	<u>£ 4,076,184</u>	<u>£ 3,741,010</u>
The historical cost of the above investments amounts to:	<u>£ 3,633,156</u>	<u>£ 3,521,243</u>

The following material investments are over 5% by value of the investments held

	<b>2021 Market value £</b>	<b>2020 Market value £</b>
HSBC FTSE All Share Index	-	302,095
Ruffer Charity Assets Trust Account	2,231,923	2,010,192
	<u>£ 2,231,923</u>	<u>£ 2,312,287</u>

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

**12. TANGIBLE FIXED ASSETS**

	<b>Property £</b>	<b>Motor Vehicles £</b>	<b>Equipment £</b>	<b>Charity Total £</b>	<b>Subsidiary - Shop Equipment £</b>	<b>Consolidated Total £</b>
<i>Cost</i>						
At 1 January 2021	635,602	41,515	46,469	723,586	34,871	758,457
Additions in year	-	-	27,943	27,943	36,387	64,330
Disposals in year	(267,900)	-	(34,079)	(301,979)	(19,697)	(321,676)
At 31 December 2021	<u>367,702</u>	<u>41,515</u>	<u>40,333</u>	<u>449,550</u>	<u>51,561</u>	<u>501,111</u>
<i>Depreciation</i>						
At 1 January 2021	72,727	35,951	41,382	150,060	23,055	173,115
Charge for year	10,033	1,391	4,744	16,168	5,156	21,324
Disposals in year	(45,989)	-	(32,953)	(78,942)	(19,557)	(98,499)
At 31 December 2021	<u>36,771</u>	<u>37,342</u>	<u>13,173</u>	<u>87,286</u>	<u>8,654</u>	<u>95,940</u>
<i>Net book value</i>						
At 31 December 2021	<u>£ 330,931</u>	<u>£ 4,173</u>	<u>£ 27,160</u>	<u>£ 362,264</u>	<u>£ 42,907</u>	<u>£ 405,171</u>
At 31 December 2020	<u>£ 562,875</u>	<u>£ 5,564</u>	<u>£ 5,087</u>	<u>£ 573,526</u>	<u>£ 11,816</u>	<u>£ 585,342</u>

All fixed assets are held for direct charitable purposes in Designated Funds.

**YORK AGAINST CANCER**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2021**

<b>13. DEBTORS</b>	<b>Charity 2021 £</b>	<b>Consolidated 2021 £</b>	<b>Charity 2020 £</b>	<b>Consolidated 2020 £</b>
Amounts owed by subsidiary	92,809	-	95,637	-
Prepayments	6,488	6,596	9,250	13,902
Accrued income	430,000	430,000	446,909	448,243
Other debtors	11,561	13,175	140	140
	<b>£ 540,858</b>	<b>£ 449,771</b>	<b>£ 551,936</b>	<b>£ 462,285</b>

**14. CREDITORS: amounts falling due  
within one year**

Trade creditors	2,445	3,488	30,378	33,524
Project creditors	476,711	476,711	444,038	444,038
Taxation and social security	3,146	6,325	3,128	8,730
Accruals	14,187	28,949	8,893	11,693
Other creditors	2,030	2,030	1,122	1,122
	<b>£ 498,519</b>	<b>£ 517,503</b>	<b>£ 487,559</b>	<b>£ 499,107</b>

**15. CREDITORS: amounts falling due  
after one year**

Project creditors	<b>£ 537,202</b>	<b>£ 537,202</b>	<b>£ 961,016</b>	<b>£ 961,016</b>
-------------------	------------------	------------------	------------------	------------------

**16. DESIGNATED FUNDS (consolidated)**

The Charitable Company transfers to designated funds sufficient resources to meet such commitments, as shown below.

<b>Designated Funds - 2021</b>	<b>Balance 01/01/2021 £</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Transfers £</b>	<b>Balance 31/12/2021 £</b>
Cancer Care Centre	5,382	-	(5,382)	-	-
Cancer Care Centre - New Centre	-	-	-	466,500	466,500
Complementary Therapy	6,364	-	(6,364)	-	-
Education Project	-	-	(2,588)	2,588	-
Minibus	28,000	-	-	8,000	36,000
Patient Travel	10,000	-	-	-	10,000
Robotic Surgery Project	-	-	-	680,000	680,000
Fixed Assets Fund	585,342	-	7,230	(187,401)	405,171
<b>Total</b>	<b>£ 635,088</b>	<b>£ -</b>	<b>£ (7,104)</b>	<b>£ 969,687</b>	<b>£ 1,597,671</b>

<b>Designated Funds - 2020</b>	<b>Balance 01/01/2020 £</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Transfers £</b>	<b>Balance 31/12/2020 £</b>
Cancer Care Centre	31,500	-	(26,118)	-	5,382
Complementary Therapy	35,480	-	(29,116)	-	6,364
Education Project	-	-	(7,170)	7,170	-
Minibus	-	-	-	28,000	28,000
Patient Travel	-	-	-	10,000	10,000
Fixed Assets	600,882	-	(18,530)	2,990	585,342
<b>Total</b>	<b>£ 667,862</b>	<b>£ -</b>	<b>£ (80,934)</b>	<b>£ 48,160</b>	<b>£ 635,088</b>

**Cancer Care Centre**

The Board is committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

### 16. DESIGNATED FUNDS (consolidated continued)

#### Cancer Care Centre - New Centre

The charity has set aside an initial budget for the provision of a new cancer care centre to be spent over the next year.

#### Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

#### Minibus

The trustees have set aside monies for the purchase of a new minibus which will be purchased next year.

#### Patient Travel

The trustees have set aside monies to fund Patient Travel and this will be reviewed next year once demand is known.

#### Robotic Surgery Project

During the year the charity started conversations with the NHS regarding supporting the Robotic Surgery facilities. Since the year end a formal commitment was made of £680,000.

#### Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

#### Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

### 17. RESTRICTED FUNDS (consolidated)

	Balance 01/01/2021	Income	Expenditure	Transfers	Balance 31/12/2021
	£	£	£	£	£
<b>Restricted Funds - 2021</b>					
Mobile Chemotherapy Unit	142,348	-	(5,382)	-	136,966
Mouth Cancer	1,677	-	-	-	1,677
Total 2021	£ 144,025	£ -	(£ 5,382)	£ -	£ 138,643
	Balance 01/01/2020	Income	Expenditure	Transfers	Balance 31/12/2020
	£	£	£	£	£
<b>Restricted Funds - 2020</b>					
Mobile Chemotherapy Unit	142,069	600	(321)	-	142,348
Prostate Cancer	12,222	-	(12,222)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2020	£ 155,968	£ 600	(£ 12,543)	£ -	£ 144,025

#### Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

#### Prostate Cancer

50% of the R U taking the P monies raised where to be allocated to prostate cancer research.

#### Mouth Cancer

Monies raised for the Head and Neck cancer department.

**YORK AGAINST CANCER**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2021**

**18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS**

	<b>General Funds £</b>	<b>Designated Funds £</b>	<b>Restricted Funds £</b>	<b>Total 2021 £</b>
Fund balances at 31 December 2021 are represented by:				
Tangible fixed assets	-	405,171	-	405,171
Investments	3,396,184	680,000	-	4,076,184
Current assets	700,267	512,500	138,643	1,351,410
Current liabilities	(517,503)	-	-	(517,503)
Long term liabilities	(537,202)	-	-	(537,202)
	<b>£ 3,041,746</b>	<b>£ 1,597,671</b>	<b>£ 138,643</b>	<b>£ 4,778,060</b>

  

	<b>General Funds £</b>	<b>Designated Funds £</b>	<b>Restricted Funds £</b>	<b>Total 2020 £</b>
Fund balances at 31 December 2020 are represented by:				
Tangible fixed assets	-	585,342	-	585,342
Investments	3,741,010	-	-	3,741,010
Current assets	1,222,644	49,746	144,025	1,416,415
Current liabilities	(499,107)	-	-	(499,107)
Long term liabilities	(961,016)	-	-	(961,016)
	<b>£ 3,503,531</b>	<b>£ 635,088</b>	<b>£ 144,025</b>	<b>£ 4,282,644</b>

**19. OPERATING LEASE COMMITMENTS**

As at 31 December 2021 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

	<b>At 31 December 2021</b>		<b>At 31 December 2020</b>	
	<b>Land and buildings £</b>	<b>Office equipment £</b>	<b>Land and buildings £</b>	<b>Office equipment £</b>
Total operating leases payable:				
Within one year	40,298	-	15,000	-
Between two and five years	127,610	-	-	-

**20. RELATED PARTIES**

During the year the Charitable Company paid £2,829 (2020 £2,620) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £107 (2020 £nil) owing to HPH Chartered Accountants.

During the year the Charitable Company paid £2,160 (2020 £nil) to Harrowells Solicitors for legal fees, a firm in which the Charitable Company's Director, Robert Onyett, is a director.

During the year the wife of a director Ian Yeowart was paid £1,300 for temporary employment cover.

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

### 21. CASH FLOW NOTES

RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES	2021 £	2020 £
Net income/(expenditure) for the reporting period	495,416	24,290
Adjustments for:		
Depreciation charges	21,324	18,530
Gains on sale of fixed assets	(28,554)	-
(Gains)/Losses on investments	(385,562)	(171,077)
Dividends, interest and rents from investments	(45,102)	(49,291)
Increase in stocks	119	1,964
Increase in debtors	12,514	232,045
(Increase)/Decrease in creditors	(405,418)	(419,781)
Net cash used in operating activities	£ (335,263)	£ (363,320)
<b>ANALYSIS OF CASH AND CASH EQUIVALENTS</b>		
Cash at bank and in hand	846,463	898,835
<b>Total cash and cash equivalents</b>	<b>£ 846,463</b>	<b>£ 898,835</b>

### ANALYSIS OF CHANGES IN NET DEBT

	At 01/01/2021 £	Cash-flows £	At 31/12/2021 £
Cash	898,835	(52,372)	846,463

### 22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

**YORK AGAINST CANCER**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**24. COMPARATIVE INFORMATION**

	<b>Unrestricted</b>			<b>Year ended</b>
	<b>General</b>	<b>Designated</b>	<b>Restricted</b>	<b>31 Dec</b>
	<b>Fund</b>	<b>Funds</b>	<b>Funds</b>	<b>2020</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>Income and endowments from:</b>				
Donations and legacies	182,105	-	600	182,705
Other trading activities	157,863	-	-	157,863
Investments	49,291	-	-	49,291
<b>Total</b>	<b>389,259</b>	<b>-</b>	<b>600</b>	<b>389,859</b>
<b>Expenditure on:</b>				
Raising funds	181,336	-	-	181,336
Charitable activities	261,833	80,934	12,543	355,310
<b>Total</b>	<b>443,169</b>	<b>80,934</b>	<b>12,543</b>	<b>536,646</b>
<b>Net expenditure before losses on investments</b>	<b>(53,910)</b>	<b>(80,934)</b>	<b>(11,943)</b>	<b>(146,787)</b>
Net gains on investments	171,077	-	-	171,077
<b>Net income/(expenditure)</b>	<b>117,167</b>	<b>(80,934)</b>	<b>(11,943)</b>	<b>24,290</b>
<b>Transfers between funds</b>	<b>(48,160)</b>	<b>48,160</b>	<b>-</b>	<b>-</b>
<b>Net movement in funds</b>	<b>69,007</b>	<b>(32,774)</b>	<b>(11,943)</b>	<b>24,290</b>
<b>Reconciliation of funds:</b>				
Total funds brought forward	3,434,524	667,862	155,968	4,258,354
<b>Total funds carried forward</b>	<b>£ 3,503,531</b>	<b>£ 635,088</b>	<b>£ 144,025</b>	<b>£ 4,282,644</b>